Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More
you are here: HomeNewsTrendsHealth

Dr Reddy's working on stability data on 2 to 8 degrees temperature range for Sputnik V vaccine

The doses will be kept outside for 15-20 minutes before being administered to the people.

April 14, 2021 / 05:41 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Dr Reddy's Laboratories is in the process of generating additional stability data for Russia's COVID-19 vaccine Sputnik V, which has a storage condition of -18 C, on 2 to 8 C, a senior official of the drug maker said on Wednesday.

Deepak Sapra, Dr Reddy's Chief Executive Officer, API and Services said in a press conference that the vaccine will be imported in a frozen condition from Russian Direct Investment Fund (RDIF) with which it has an agreement to distribute 125 million human doses ( 250 million vials) in India, maintaining -18 to -22.

Also Read: COVID-19 | 50 million doses of Sputnik V vaccine to be available every month by summer: RDIF

Also Read: Here is how Sputnik V stacks up against Covishield and Covaxin

The doses will be kept outside for 15-20 minutes before being administered to the people.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"In addition to the product which is at -18 C, today we are in the process of generating additional stability data on the 2 to 8 C temperature range. This data will be available in a few months, after which we will make the necessary amendment request to the regulator and request for the storage condition to be modified to 2 to 8 C," Sapra told reporters.

Also Read: Sputnik V COVID-19 vaccine approved in India: All your questions answered

He said necessary cold storage infrastructure is in place to distribute Sputnik V vaccine in India, which will be available during the current quarter.

Follow our LIVE blog for latest updates of the novel coronavirus pandemic

Dr Reddy's Laboratories on Tuesday said it has received approval from Indian drug regulator for restricted emergency use of COVID-19 vaccine Sputnik in the country.

The company has received the permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act, Dr Reddy's had said in a regulatory filing.

In September 2020, Dr. Reddy's and RDIF entered into a partnership to conduct clinical trials of the Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the rights for distribution of the first 100 million doses in India.

Later it was enhanced to 125 million. Sapre further said the quantity can be further enhanced with mutual agreement.

Follow our full coverage of the coronavirus pandemic here.
PTI
first published: Apr 14, 2021 05:35 pm

stay updated

Get Daily News on your Browser
Sections